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Abstract: There are well-recognised associations between excessive gestational weight gain (GWG)
and adverse pregnancy outcomes, including an increased risk of pre-eclampsia, gestational diabetes
and caesarean birth. The aim of the OPTIMISE randomised trial was to evaluate the effect of dietary
and exercise advice among pregnant women of normal body mass index (BMI), on pregnancy and
birth outcomes. The trial was conducted in Adelaide, South Australia. Pregnant women with a body
mass index in the healthy weight range (18.5–24.9 kg/m2) were enrolled in a randomised controlled
trial of a dietary and lifestyle intervention versus standard antenatal care. The dietitian-led dietary
and lifestyle intervention over the course of pregnancy was based on the Australian Guide to Healthy
Eating. Baseline characteristics of women in the two treatment groups were similar. There was no
statistically significant difference in the proportion of infants with birth weight above 4.0 kg between
the Lifestyle Advice and Standard Care groups (24/316 (7.59%) Lifestyle Advice versus 26/313 (8.31%)
Standard Care; adjusted risk ratio (aRR) 0.91; 95% confidence interval (CI) 0.54 to 1.55; p = 0.732).
Despite improvements in maternal diet quality, no significant differences between the treatment
groups were observed for total GWG, or other pregnancy and birth outcomes.
Keywords: dietary and lifestyle intervention; gestational weight gain; randomised controlled trial
1. Introduction
Obesity represents a significant global health burden, with the World Health Organisation
highlighting the importance of weight gain prevention in adults of healthy weight, particularly among
women of reproductive age [1]. In any given 5-year period, 20% of women of reproductive age
have sufficient weight gain to progress them into a higher body mass index (BMI) category [2,3].
Furthermore, the rate of weight gain is highest (approximately 700 g per year) among women of
normal BMI [4,5]. Pregnancy often represents a significant turning point in a woman’s cardiovascular
and metabolic health trajectory secondary to pregnancy-related changes, including relative insulin
resistance, which promotes weight gain [6], and risk of developing obesity subsequently [7,8].
There is substantial observational literature relating to gestational weight gain (GWG), which
has been summarised by the Institute of Medicine (IoM) [9,10]. These recommendations advocate a
GWG of 11.5 to 16.0 kg for women of normal body mass index (BMI 18.5–24.9 kg/m2) [9,10]. However,
approximately 40% of women gain in excess of this amount [10]. There are well-recognised associations
between excessive GWG and adverse pregnancy outcomes for the woman, including an increased
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risk of pre-eclampsia, gestational diabetes and caesarean birth [11–14]. There are also longer-term
health consequences for women, including post-partum weight retention (PPWR) and development of
obesity [15–17], with over 70% of women of normal BMI retaining more than 5 kg of weight 1 year
after birth [18,19]. Women with excessive GWG also have a greatly increased risk of developing both
diabetes [20,21] and cardiovascular disease in later life [22–25].
Excessive GWG is a well-recognised risk factor for high infant birth weight and is independently
associated with an increased risk of child obesity in the offspring [26–28], thereby creating a vicious
cycle in which the intergenerational effects of obesity are perpetuated [29]. Specifically, the risk of early
childhood obesity increases by a factor of 1.08 (95% CI 1.03–1.14) per kilogram of maternal weight gained
above the IoM recommendations [30]. Furthermore, it has been suggested that high maternal weight
gain may induce a persisting susceptibility of an individual to an obesogenic environment [30,31].
There is also increasing evidence for an effect of excessive maternal GWG on subsequent cardiovascular
risk and hypertension in children [27,32] and adolescents [33].
Despite recognition of the associations between excessive GWG in women of normal BMI during
pregnancy and beyond, there is more limited information describing effective antenatal dietary
interventions to optimise weight gain and improve health. In a systematic review of the literature,
12 randomised trials involving 2713 pregnant women were identified [34]. Of these trials, 8 specifically
recruited 1048 women of normal BMI, although only 5 reported clinical outcomes (714 women) [34].
Providing a combined dietary and lifestyle intervention during pregnancy was associated with a
modest 1.25 kg difference in weight gain (5 studies, 714 women) [34]. However, the effect on clinical
pregnancy outcomes was less clear, being reported in only 2 trials, with 243 women [34].
The aim of the OPTIMISE randomised trial was therefore to evaluate the effect of dietary and
exercise advice among pregnant women of normal BMI, on pregnancy and birth outcomes.
2. Materials and Methods
2.1. Trial Design
We conducted a randomised controlled trial, in which women with a BMI of 18.5 to 24.9 kg/m2,
and a singleton pregnancy between 10 + 0–20 + 0 weeks were eligible to participate [35]. Women with
a multiple pregnancy, or with diabetes (type 1 or type 2) diagnosed prior to pregnancy were excluded.
Ethical approval was provided by the research ethics committee of the Women’s and Children’s
Hospital (Adelaide, South Australia), approval number HREC/13/WCHN/152, and the study registered
with the Australian and New Zealand Clinical Trials Registry (ACTRN 12614000583640). Recruitment
to the trial commenced in June 2014.
Women were screened for eligibility at the time of their first antenatal appointment. All women
presenting to the Women’s and Children’s Hospital had their height and weight measured, and BMI
calculated by research staff. Eligible women were provided with information about the study and
were counselled by a research assistant, prior to their provision of written consent to participate.
Randomisation: We used a computer-based randomisation service in the Discipline of Obstetrics
and Gynaecology, The University of Adelaide. The randomisation schedule used balanced variable
blocks with stratification for parity (0 versus 1 or more) and was prepared by an investigator who was
not involved with recruitment or clinical care.
Women were randomised to either the ‘Lifestyle Advice Group’ or the ‘Standard Care Group’.
Blinding of participants was not possible given the nature of the intervention, but where possible,
antenatal care-providers, outcome assessors and data analysts were blinded to treatment allocation.
Treatment Allocation: Women randomised to the Lifestyle Advice Group received an intervention
consisting of six sessions provided across the course of pregnancy. Three sessions were face-to-face,
with two provided by the dietitian shortly after trial entry and again at 28 weeks’ gestation, and
one provided by a research assistant at 36 weeks’ gestation. Women also received three telephone
calls from the research assistant at 20, 24 and 32 weeks’ gestation. The dietary advice provided was
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consistent with current Australian dietary standards [36], while specifically maintaining a balance of
carbohydrates, fat and protein, and encouraging women to reduce their intake of energy dense and
non-core foods high in refined carbohydrates and saturated fats. Women were advised to increase their
intake of fibre, and to consume two servings of fruit, five servings of vegetables and three servings of
dairy each day [36–38].
Tailoring of the intervention was informed by stage theories of health decision making where an
individual progresses through a series of cognitive phases when undertaking behavioural change [39].
The initial planning session with a research dietitian provided women with written dietary and activity
information, an individual diet and physical activity plan, recipe book and example menu plans.
Women were encouraged to set achievable goals for dietary and exercise change, supported to make
these lifestyle changes and to self-monitor their progress, using a SMART goals approach. The SMART
Goal approach includes setting goals that are specific, measurable, achievable, realistic and timely.
Therefore, a SMART goal incorporates all of these criteria to increase the chances of goal achievement.
These principles were reinforced at subsequent contacts with research staff [37,38].
Women who were randomised to the Standard Care Group received their antenatal care according
to hospital guidelines, which did not include information relating to dietary intake, physical activity or
weight gain during pregnancy.
All women were asked to complete a food frequency questionnaire, physical activity questionnaire
and quality of life assessments at trial entry, 28 and 36 weeks’ gestation and six months postpartum.
Each woman’s weight was recorded at trial entry and at 36 weeks’ gestation or nearest to birth, with
gestational weight gain determined as the difference between weight at 36 weeks and trial entry.
All women were offered a research ultrasound at 28 and 36 weeks’ gestation to assess foetal growth
(results not presented in this manuscript). After birth, information relating to birth and infant outcomes
was obtained from the case notes by the research assistant, who remained blinded to the woman’s
allocated treatment group.
Consistent with state-wide clinical practice guidelines, all women were screened for gestational
diabetes at approximately 28 weeks’ gestation [40]. During the course of the trial, diagnostic criteria
for gestational diabetes changed across the state from a positive 75 g oral glucose tolerance test with
fasting blood glucose > 5.5 mmol/L, or 2 h ≥ 7.8 mmol/L, to fasting blood glucose ≥ 5.1 mmol/L,
1 h ≥ 10.0 mmol/L, or 2 h ≥ 8.5 mmol/L [40]. Women diagnosed with gestational diabetes remained
in the study and were offered treatment with further dietary modification and metformin or insulin
added as required to maintain appropriate glycaemic control [40].
2.2. Outcome Measures
The primary trial outcome was the proportion of infants with birth weight > 4 kg. A range of
secondary study outcomes were collected and listed below.
2.2.1. Secondary Infant Outcomes
Adverse outcomes for the infant: including preterm birth before 37 weeks’ gestation; perinatal
mortality (either stillbirth (intrauterine foetal death after trial entry and prior to birth), or infant death
(death of a live born infant prior to hospital discharge, and excluding lethal congenital anomalies));
infant birth weight; infant birth weight < 2500 g; infant birth weight > 4500 g; large for gestational age
defined as infant birth weight > 90th percentile for gestational age and infant sex; small for gestational
age defined as infant birth weight < 10th percentile for gestational age and infant sex; hypoglycaemia
requiring intravenous treatment; admission to neonatal intensive care unit or special care baby unit;
hyperbilirubinaemia requiring phototherapy; nerve palsy; fracture; birth trauma; shoulder dystocia;
corticosteroid use; respiratory distress syndrome (with moderate or severe respiratory disease defined as
mean airway pressure > 10 cm H2O and/or inspired oxygen fraction (FiO2) > 0.80 with ventilation) [41];
discharge home on oxygen; patent ductus arteriosus; proven systemic infection requiring treatment;
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retinopathy of prematurity; necrotising enterocolitis; neonatal encephalopathy [42]; seizures; length of
hospital stay; and infant not exclusively breast fed at hospital discharge.
2.2.2. Maternal Antepartum, Labour and Birth Outcomes
Adverse outcomes for the woman: including maternal hypertension and pre-eclampsia
(in accordance with recognised Australasian Society for the Study of Hypertension in Pregnancy
criteria) [43]; maternal gestational diabetes; need for and length of antenatal hospital stay; antepartum
haemorrhage requiring hospitalisation; preterm prelabour ruptured membranes; chorioamnionitis;
need and reason for induction of labour; any antibiotic use during labour; caesarean section; postpartum
haemorrhage (blood loss > 600 mL); perineal trauma; wound infection; endometritis; length of postnatal
hospital stay; thromboembolic disease; maternal death.
2.2.3. Maternal Weight Change
Maternal weight changes: including total gestational weight gain; average weekly gestational
gain; gestational weight gain below, within and above IoM recommendations [10]; and anthropometric
assessment (skin-fold thickness measurement (SFTM), body circumferences and bio-impedance to
assess adiposity).
2.2.4. Maternal Diet and Physical Activity
Maternal changes in diet and physical activity as measured by questionnaires completed by
the woman at trial entry, 28 and 36 weeks’ gestation (Harvard Semi-quantitative Food Frequency
Questionnaire [44,45], and the Short Questionnaire to Assess Health-enhancing physical activity
(SQUASH) [46]).
2.2.5. Maternal Quality of Life
Maternal quality of life and emotional wellbeing as measured by questionnaires completed by the
woman at trial entry, 28 weeks and 36 weeks’ gestation relating to quality of life (as measured using
the SF12 Health Survey Questionnaire) [47]; preferences for treatment, satisfaction with care; anxiety
(as measured by the Short Form Spielberger State Trait Inventory [48]) and depression (as measured by
the Edinburgh Postnatal Depression Scale [49]).
2.3. Sample Size Estimate
The primary clinical endpoint was the incidence of infants born with birth weight > 4 kg, with an
estimated incidence in women eligible for this trial of 8.72% [50]. To detect a difference from 8.72% to
3.89% (alpha 0.05; power 70%), we required 624 women.
2.4. Analysis and Reporting of Results
All analyses followed a pre-specified statistical analysis plan, as shown in Supplementary File
1. Baseline characteristics of all randomised women were examined descriptively as an indication of
comparable treatment groups, and included maternal age, parity, race, height, weight, smoking status,
past obstetric history and a diagnosis of previous gestational diabetes. Primary and secondary outcomes
were analysed on an “intention to treat” basis, according to the treatment allocated (Lifestyle Advice
or Standard Care) at the time of randomisation. Continuous outcomes were analysed using linear
regression, and binary outcomes were analysed using log binomial regression. Outcomes measured
at multiple time points included a time-by-treatment interaction term, with generalised estimating
equations used to account for correlation between repeated measures.
As specified in the Statistical Analysis Plan, the primary analyses were adjusted analyses based
on imputed data. Unadjusted analyses, and analyses on unimputed data (not presented), were also
performed as secondary sensitivity analyses. Adjusted models included the stratification variable
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(parity) as well as BMI (continuous variable), smoking, socio-economic status (as indicated by the
Australian Bureau of Statistics’ 2011 Socio-economic Index for Areas—Index of Relative Socio-economic
Disadvantage (SEIFA IRSD) quintile) and maternal age at trial entry as covariates.
There was one missing value for the primary outcome and other infant birth weight outcomes;
many other outcomes (including infant anthropometry, infant and maternal delivery data) had less
than 1% missing data, while infant SFTM and other maternal antenatal measures had between 20–40%
missing data. Multiple imputation by the fully conditional specification (chained equations) method
was used to create 100 complete datasets for analysis [51]. The imputation model included all outcomes,
all stratification variables, maternal baseline height, weight and gestational age, and maternal weight
at 36 weeks’ gestation. Estimates were derived in the standard manner by combining the estimates
from each imputation using Rubin’s rules [51]. As there was only one missing value for the primary
outcome, no missing not at random (MNAR) sensitivity analyses were performed. Analyses were
performed using Stata version 15 (StataCorp, 77845 Texas, USA).
Data cannot be made publicly available because of ethics and Institutional Review Board
restrictions. However, researchers can apply for data access to the corresponding author.
3. Results
3.1. Participant Characteristics
Between June 2014 and April 2017, 2602 eligible women were approached to participate, with 645
randomised, 323 (50.1%) to Lifestyle Advice and 322 (49.9%) to Standard Care, as shown in Figure 1.
Four women were randomised in error prior to the start of the trial (all four from the Lifestyle Advice
Group) and were not included in analyses, leaving a total of 641 women (319 Lifestyle Advice Group
and 322 Standard Care). A further four women (two in each group) terminated pregnancies for
foetal anomalies; four women suffered a stillbirth (all in the Standard Care Group); and two liveborn
infants died after birth (both in the Lifestyle Advice Group). Two stillbirths occurred in the setting of
chorioamnionitis prior to 24 weeks’ gestation; one occurred at 40 weeks secondary to Escherichia coli
sepsis; and one unexplained stillbirth occurred at 39 weeks. One liveborn infant died secondary to
extreme prematurity following spontaneous birth at 23 weeks, and the second infant, born at 36 weeks,
died at a few hours of age from pulmonary hypoplasia secondary to multicystic dysplastic kidney
disease. Overall, 633 women and 629 liveborn infants were included in the analyses, with adequate
data available for 628 (99.8%) for the primary outcome of birth weight above 4.0 kg. There were no
maternal deaths.
The baseline characteristics of women in the two treatment groups were similar at trial entry, as
shown in Table 1. The median BMI of the cohort was 22.20 kg/m2 (inter-quartile range (IQR) 20.87
to 23.60 kg/m2). The mean maternal age of participants was 31.5 years, with 59% of women in their
first ongoing pregnancy. The median gestational age at trial entry was approximately 16.3 weeks
(IQR 14.57 to 18.14 weeks), 4.4% of women were smokers, and 30.5% of women were from the highest
two quintiles of social disadvantage.
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Figure 1. Flow of participants in the trial. Notes: 1 This number excludes four women who were
randomised in error prior to trial registration. 2 Termination of pregnancy (TOP) 3 Three hundred and
twelve infants with non-missing data included in raw data analysis, one infant with missing data had
outcomes imputed and was therefore included in the imputed analysis. 4 Stillbirths excluded from
infant outcomes analysis but included for analysis of maternal antenatal outcomes only.
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Table 1. Baseline characteristics.
Characteristic Lifestyle Advice(n = 316) **
Standard Care
(n = 317) ** Overall (n = 633) **
Maternal age in (years) * 31.60 (4.63) 31.45 (4.63) 31.53 (4.76)
Gestational age at entry (weeks) + 16.21 (14.43, 18.14) 16.29 (14.71, 18.14) 16.29 (14.57, 18.14)
Body mass index at entry (kg/m2) + 22.17 (20.81, 23.70) 22.20 (20.90, 23.46) 22.20 (20.87, 23.60)
Height at trial entry + 165.18 (7.18) 164.74 (7.18) 164.96 (7.17)
Weight at trial entry + 60.56 (6.92) 60.22 (6.92) 60.39 (6.88)
Public patient # 312 (98.73) 315 (99.37) 627 (99.05)
Ethnicity #
Caucasian 212 (67.09) 215 (67.82) 427 (67.46)
Asian 50 (15.82) 45 (14.20) 95 (15.01)
Indian, Pakistani, Sri Lankan 22 (6.96) 29 (9.15) 51 (8.06)
Other 32 (10.13) 28 (8.83) 60 (9.47)
Nulliparous # 189 (59.81) 186 (58.68) 375 (59.24)
Smoker # 15 (4.75) 13 (4.10) 28 (4.42)
SEIFA IRSD 1 Quintile # ˆ
Q1 (most disadvantaged) 48 (15.19) 58 (18.30) 106 (16.75)
Q2 78 (24.68) 93 (29.34) 87 (13.74)
Q3 48 (15.19) 39 (12.30) 156 (24.64)
Q4 80 (25.32) 76 (23.97) 156 (24.64)
Q5 (least disadvantaged) 62 (19.62) 51 (16.09) 113 (17.85)
* = mean and standard deviation. + = median and interquartile range. # = number and %. ˆ = socioeconomic index
of relative social disadvantage as measured by SEIFA. ** = includes all women randomised who did not withdraw
consent to use their data, and who did not suffer miscarriage or termination of pregnancy prior to 20 weeks gestation.
Note that numbers reported in this table incorporate some corrections post-randomisation to parity categories used
(as stratification variable) when randomising participants. Eighteen participants were categorised as having parity 0
at randomisation when they in fact had parity 1+, and five participants were categorised as having parity 1+ at
randomisation when they in fact had parity 0. 1 SEIFA IRSD: Socio-economic Index for Areas—Index of Relative
Socio-economic Disadvantage.
3.2. Pre-Specified Infant Outcomes
There was no statistically significant difference in the proportion of infants with birth weight
above 4.0 kg between the Lifestyle Advice and Standard Care groups (24/316 (7.59%) Lifestyle Advice
versus 26/313 (8.31%) Standard Care; adjusted risk ratio (aRR) 0.91; 95% confidence interval (CI) 0.54 to
1.55; p = 0.732), as shown in Table 2.
3.3. Maternal Diet Quality
When compared with women who received standard care, women who received lifestyle advice
demonstrated improvements in their reported dietary quality as measured by the healthy eating index
(HEI) at both 28 (74.35 ± 7.65 Lifestyle Advice Group vs. 72.11 ± 8.21 Standard Care Group; adjusted
mean difference 2.21; 95% CI 0.98 to 3.45; p < 0.001) and 36 weeks’ gestation (74.10 ± 8.77 Lifestyle
Advice Group vs. 72.50 ± 8.43 Standard Care Group; adjusted mean difference 1.57; 95% CI 0.22 to
2.91; p = 0.023), as shown in Table 3. There were no observed differences in reported physical activity,
as shown in Table 3.
3.4. Pre-Specified Maternal Antepartum Outcomes
Despite improvements in maternal diet quality, there were no differences between the treatment
groups observed for total GWG (11.32 ± 3.96 kg Lifestyle Advice versus 11.70 ± 3.78 kg Standard
Care; adjusted mean difference (aMD)—0.37; 95% CI—0.97 to 0.23; p = 0·227), as shown in Table 4.
Similarly, there were no observed differences in the proportion of women who gained weight above
(28 (8.72%) Lifestyle Advice versus 41 (13.16%) Standard Care; aRR 0.58; 95% CI 0.32 to 1.04; p = 0.066)
or below (160 (50.71%) Lifestyle Advice versus 162 (51.68%) Standard Care; aRR 0.85; 95% CI 0.60 to
1.21; p = 0.366) the IOM recommendations, as shown in Table 4.
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Table 2. Pre-specified infant outcomes by treatment group.
Outcome Lifestyle Advice(n = 316) **
Standard Care









Birthweight > 4 kg a 24 (7.59) 26 (8.31) 0.91 (0.54, 1.56) 0.739 0.91 (0.54, 1.55) 0.732
Birthweight (g) b 3291.97 (586.20) 3370.92 (511.24) −78.96 (−164.95, 7.03) 0.072 −78.39 (−164.00, 7.22) 0.073
Birthweight z-score b −0.01 (0.87) 0.04 (0.89) −0.05 (−0.18, 0.09) 0.503 −0.04 (−0.18, 0.09) 0.532
Gestational age at delivery (weeks) b 39.12 (2.38) 39.46 (1.63) −0.33 (−0.65, −0.02) 0.040 −0.34 (−0.66, -0.02) 0.039
Large for gestational age a 22 (6.96) 25 (8.00) 0.87 (0.50, 1.51) 0.621 0.88 (0.51, 1.52) 0.641
Small for gestational age a 21 (6.65) 25 (8.01) 0.83 (0.47, 1.45) 0.512 0.84 (0.48, 1.47) 0.545
Birthweight below 2.5kg a 20 (6.33) 15 (4.82) 1.31 (0.69, 2.52) 0.411 1.32 (0.69, 2.54) 0.399
Birthweight > 4.5 kg d 0 (0.00) 2 (0.64) 0.246
Neonatal intensive/special
care nursery admission a 27 (8.54) 34 (10.89) 0.78 (0.49, 1.27) 0.323 0.80 (0.50, 1.30) 0.368
Neonatal death d 2 (0.63) 0 (0.00) 0.499
Hypoglycaemia a 10 (3.16) 23 (7.41) 0.43 (0.21, 0.88) 0.022 0.44 (0.21, 0.91) 0.026
Hyperbilirubinaemia a 23 (7.28) 15 (4.80) 1.52 (0.81, 2.85) 0.196 1.53 (0.82, 2.87) 0.181
Shoulder dystocia a 9 (2.85) 13 (4.16) 0.68 (0.30, 1.58) 0.373 0.69 (0.30, 1.59) 0.386
Nerve palsy a, d 0 (0.00) 0(0.00) – –
Bone fracture a, d 0 (0.00) 1 (0.32) – 0.497 –
Birth trauma a, d 1 (0.32) 2 (0.64) – 0.622 –
a Number and percentage, estimates are relative risks and 95% confidence interval. b Mean and standard deviation, estimates are differences in means and 95% confidence interval. d Due
to small numbers of events, no analysis of these outcomes was possible; the p value for comparison between groups has been calculated using a Fisher’s Exact Test. For nerve palsy, there
were no events in either group. c Adjusted analyses: all outcomes were adjusted for the stratification variable parity (0 vs. 1+), maternal age (continuous), maternal pre-pregnancy
body mass index (BMI) (continuous) and SEIFA IRSD Quintile. ** = includes all infants of women randomised who did not withdraw consent to use their data, and who did not suffer
miscarriage or termination of pregnancy prior to 20 weeks gestation, or stillbirth.
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Table 3. Pre-specified maternal antepartum diet quality and physical activity outcomes by treatment group.
Outcome Lifestyle Advice(n = 316) **
Standard Care









Healthy Eating Index b, e <0.001 * < 0.001 *
Trial Entry 72.94 (9.22) 73.56 (7.89) −0.62 (−1.96, 0.72) 0.362 −0.66 (−1.99, 0.68) 0.334
28 Weeks 74.35 (7.65) 72.11 (8.21) 2.25 (1.01, 3.48) <0.001 2.21 (0.98, 3.45) < 0.001
36 Weeks 74.10 (8.77) 72.50 (8.43) 1.60 (0.25, 2.95) 0.020 1.57 (0.22, 2.91) 0.023
Total Energy (kJ) b, e 0.017 * 0.017 *
Trial Entry 8917.75 (3182.65) 8899.67 (3796.04) 18.07 (−525.98, 562.13) 0.948 20.93 (−516.71, 558.57) 0.939
28 Weeks 9358.47 (3782.64) 8692.51 (2829.24) 665.95 (141.52, 1190.38) 0.013 668.81 (155.43, 1182.19) 0.011
36 Weeks 8809.72 (3233.50) 8697.78 (3132.76) 111.93 (−381.78, 605.65) 0.657 114.79 (−375.44, 605.03) 0.646
Glycaemic Index b, e 0.183 * 0.183 *
Trial Entry 47.23 (4.85) 47.54 (4.88) −0.31 (−1.07, 0.45) 0.427 −0.26 (−1.01, 0.49) 0.496
28 Weeks 47.22 (3.70) 48.13 (4.46) −0.91 (−1.55, −0.27) 0.005 −0.86 (−1.50, −0.23) 0.008
36 Weeks 47.18 (4.73) 47.79 (4.57) −0.61 (−1.34, 0.12) 0.099 −0.56 (−1.28, 0.16) 0.124
Glycaemic Load b, e 0.113 * 0.113 *
Trial Entry 110.53 (48.61) 115.02 (67.51) −4.50 (−13.76, 4.76) 0.341 −4.06 (−13.15, 5.02) 0.381
28 Weeks 117.43 (55.86) 114.87 (45.96) 2.56 (−5.43, 10.54) 0.530 2.99 (−4.89, 10.87) 0.457
36 Weeks 109.28 (46.41) 113.87 (51.31) -4.59 (-12.14, 2.95) 0.233 −4.16 (−11.62, 3.31) 0.275
Metabolic Equivalent Task Score b, e 0.998 * 0.998 *
Trial Entry 9809.81 (4176.78) 9744.88 (4427.83) 64.93 (−607.56, 737.42) 0.850 82.27 (−581.63, 746.16) 0.808
28 Weeks 9085.84 (4076.53) 9028.78 (4440.41) 57.06 (−614.93, 729.06) 0.868 74.40 (−588.00, 736.81) 0.826
36 Weeks 7863.59 (4848.39) 7786.89 (4609.72) 76.70 (−664.65, 818.05) 0.839 94.04 (−637.23, 825.32) 0.801
b Mean and standard deviation, estimates are differences in means and 95% confidence interval. e Repeated measures outcomes: models included a time by intervention interaction term,
and separate estimates of treatment effect were derived at each time point regardless of the significance of this interaction term. f Adjusted analyses: all outcomes were adjusted for the
stratification variable parity (0 vs. 1+), maternal age (continuous), maternal pre-pregnancy BMI (continuous) and SEIFA IRSD Quintile. * Denotes p value testing for interaction between
treatment and time, i.e., whether effect of intervention differed between time points. ** = includes all women randomised who did not withdraw consent to use their data, and who did not
suffer miscarriage or termination of pregnancy prior to 20 weeks gestation, or stillbirth.
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Table 4. Pre-specified maternal antepartum outcomes by treatment group.
Outcome Lifestyle Advice(n = 316) **
Standard Care









Total Gestational Weight Gain (kg) b 11.32 (3.96) 11.70 (3.78) −0.39 (−0.99, 0.21) 0.205 −0.37 (−0.97, 0.23) 0.227
Average Weekly Gestational
Gain (kg) b 0.57 (0.21) 0.60 (0.21) −0.03 (−0.06, 0.01) 0.114 −0.03 (−0.06, 0.01) 0.132
Institute of Medicine Category: total
gestational weight gain d 0.168 0.177ˆ
Below 160 (50.71) 162 (51.68) 0.85 (0.60, 1.21) 0.362 0.85 (0.60, 1.21) 0.366
Within 128 (40.57) 110 (35.16) (reference) (reference)
Above 28 (8.72) 41 (13.16) 0.57 (0.32, 1.03) 0.062 0.58 (0.32, 1.04) 0.066
Institute of Medicine Category:
weekly gestational weight gain d 0.386 0.444ˆ
Below 61 (19.25) 46 (14.78) 1.40 (0.84, 2.31) 0.196 1.36 (0.82, 2.26) 0.235
Within 105 (33.12) 111 (35.47) (reference) (reference)
Above 151 (47.63) 156 (49.75) 1.03 (0.71, 1.48) 0.895 1.02 (0.70, 1.48) 0.916
Pregnancy Hypertension a 5 (1.58) 4 (1.30) 1.22 (0.33, 4.51) 0.764 1.87 (0.52, 6.70) 0.338
Pre-Eclampsia/Eclampsia a 6 (1.90) 9 (2.91) 0.65 (0.24, 1.81) 0.414 0.70 (0.25, 1.96) 0.502
Clinical Diagnosis of Gestational
Diabetes Mellitus a, † 39 (12.43) 39 (12.46) 1.00 (0.64, 1.55) 0.995 1.02 (0.66, 1.59) 0.929
Antenatal Hospital Admission a 43 (13.61) 52 (16.61) 0.82 (0.56, 1.19) 0.294 0.81 (0.56, 1.18) 0.272
Antenatal Length Stay c 0.83 (4.18) 0.42 (1.49) 1.98 (1.00, 3.92) 0.049 1.99 (1.03, 3.85) 0.042
Antepartum Haemorrhage a 4 (1.27) 7 (2.24) 0.57 (0.17, 1.91) 0.360 0.62 (0.18, 2.10) 0.443
Preterm Prelabour Ruptured
Membranes a 5 (1.58) 4 (1.28) 1.24 (0.34, 4.57) 0.748 1.17 (0.32, 4.32) 0.814
a Number and percentage, estimates are relative risks and 95% confidence interval regression models. b Mean and standard deviation, estimates are differences in means and 95%
confidence interval. c Mean and standard deviation, and estimates are relative risk ratios and 95% confidence intervals. d Number and percentage in each category, estimates are odds
ratios and 95% confidence intervals. f Adjusted analyses: all outcomes were adjusted for the stratification variable parity (0 vs. 1+), maternal age (continuous), maternal pre-pregnancy
BMI (continuous) and SEIFA IRSD Quintile. ˆ Denotes p value for a global test of any difference between categories in the multinomial logistic regression model. † Adjusted model for this
outcome required log Poisson regression with robust variance estimation due to convergence issues with the log binomial model. ** = includes all women randomised who did not
withdraw consent to use their data, and who did not suffer miscarriage or termination of pregnancy prior to 20 weeks gestation, or stillbirth.
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There were no significant differences observed between the two treatment groups with regards to
the occurrence of pregnancy-related complications, including hypertension, pre-eclampsia or eclampsia,
gestational diabetes, antepartum haemorrhage or preterm prelabour ruptured membranes, as shown in
Table 4. There were no significant differences in the number of antenatal hospital admissions between
the two groups, however, there was a borderline statistically significant difference in the mean number
of antenatal days in hospital (0.83 (4.18) Lifestyle Advice Group versus 0.42 (1.49) in the Standard Care
Group; aRR 1.99; 95% CI 1.03 to 3.85; p = 0.042). This difference can be explained by the extremely long
antenatal hospital admissions for three women in the Lifestyle Advice Group, as shown in Table 4.
Self-reported maternal quality of life was similar between groups, as shown in Table S1.
3.5. Pre-Specified Maternal Labour and Birth Outcomes
While there was a reduction in the risk of requiring induction of labour among women in the
Lifestyle Advice group (74 (23.42%) Lifestyle Advice versus 109 (34.96%) Standard Care; aRR 0.66;
95% CI 0.52 to 0.85; p = 0·001), this likely reflected chance differences in the need for induction of labour
for post-dates pregnancy (21 (28.38%) Lifestyle Advice versus 43 (39.45%) Standard Care), as shown in
Table 5. There were no significant differences observed between the two groups with regards to risk of
caesarean birth (73 (23.17%) Lifestyle Advice versus 74 (23.79%) Standard Care; aRR 0.95; 95% CI 0.72
to 1.26; p = 0.713).




(n = 316) **
Standard
Care











Chorioamnionitis a 3 (0.95) 5 (1.60) 0.59 (0.14, 2.46) 0.470 0.56 (0.14, 2.28) 0.418
Induction of Labour a 74 (23.42) 109 (34.96) 0.67 (0.52, 0.86) 0.002 0.66 (0.52, 0.85) 0.001
Antibiotics during Labour a 147 (46.52) 137 (43.75) 1.06 (0.89, 1.26) 0.486 1.04 (0.88, 1.23) 0.629
Caesarean Section a 73 (23.17) 74 (23.79) 0.97 (0.73, 1.29) 0.855 0.95 (0.72, 1.26) 0.713
Emergency Caesarean
Section a 41 (13.03) 45 (14.46) 0.90 (0.61, 1.33) 0.603 0.89 (0.60, 1.31) 0.560
Preterm Birth a 23 (7.28) 20 (6.40) 1.14 (0.64, 2.03) 0.663 1.14 (0.64, 2.03) 0.669
Postpartum Haemorrhage a 53 (16.84) 45 (14.43) 1.17 (0.81, 1.68) 0.408 1.16 (0.80, 1.67) 0.431
Perineal Trauma a 184 (58.23) 189 (60.26) 0.97 (0.85, 1.10) 0.604 0.98 (0.86, 1.11) 0.728
3rd/4th Degree Perineal
Trauma a 9 (2.85) 5 (1.60) 1.78 (0.60, 5.25) 0.296 1.69 (0.57, 4.97) 0.344
Wound Infection a 4 (1.27) 3 (0.99) 1.29 (0.29, 5.70) 0.740 1.45 (0.33, 6.39) 0.624
Postnatal Length Stay c 1.87 (1.47) 1.88 (1.54) 0.99 (0.89, 1.11) 0.906 1.00 (0.89, 1.12) 0.951
a Number and percentage of events, estimates are relative risks and 95% confidence interval. c Mean and standard
deviation, estimates are relative risk ratios and 95% confidence intervals. f Adjusted analyses: all outcomes were
adjusted for the stratification variable parity (0 vs. 1+), maternal age (continuous), maternal pre-pregnancy BMI
(continuous) and SEIFA IRSD Quintile. ** = includes all women randomised who did not withdraw consent to use
their data, and who did not suffer miscarriage or termination of pregnancy prior to 20 weeks gestation, or stillbirth.
The mean gestational age at birth was lower in the Lifestyle Advice Group (39.12 ± 2.38 weeks
Lifestyle Advice versus 39.46 ± 1.63 weeks Standard Care; aMD—0.34; 95% CI—0.66 to −0.02;
p = 0·039), as shown in Table 2. While this difference is statistically significant, the difference is
considered clinically small, and reflective of the differences in induction of labour for post-dates
pregnancy. The non-statistically significant difference observed in mean infant birth weight (3291.97 ±
586.20 g Lifestyle Advice versus 3370.92 ± 511.24 g Standard Care; aMD—78.39; 95% CI—164.00 to
7.22; p = 0.073) is also reflective of the observed difference in mean gestational age at birth; the mean
difference in birthweight z-score was not near statistical significance (aMD—0.04; 95% CI—0.18, 0.09,
p = 0.532). There were no statistically significant differences between the two groups with regards
to other infant outcomes, as shown in Table 2, or newborn anthropometric measures, as shown in
Table S2.
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3.6. Effect Modification by Maternal Pre-Pregnancy BMI
Pre-specified secondary analyses identified some evidence of effect modification by maternal
pre-pregnancy BMI, suggesting that the intervention may have been more effective in women with
higher maternal BMI in reducing infant birth weight and head, abdominal and chest circumferences, as
shown in Table S3. There was also some weak evidence suggesting a differential effect of the intervention
by parity on infant birth weight, chest and arm circumference and thigh skinfold measurement, with
lifestyle advice being more effective in reducing these measures among women in their second and
subsequent pregnancy.
4. Discussion
Our findings indicate that providing lifestyle advice during pregnancy to women with BMI
within the normal range was associated with improvements in maternal diet quality over the course
of pregnancy. However, despite improvements in maternal diet, lifestyle advice was not associated
with any differences in total gestational weight gain or risk of weight gain below or above the IOM
recommendations. There were no significant differences in clinical outcomes for either women or their
infants, including risk of infant birth weight above 4 kg.
There were a number of strengths to our randomised trial. To our knowledge, it was the largest
of its kind recruiting women with healthy BMI during pregnancy, with comprehensive reporting of
relevant maternal and infant clinical outcomes, high rates of participant follow-up and broad inclusion
criteria. Our methodology was robust, with all participating women prospectively having their height,
weight and BMI measured, use of a central randomisation service and outcome assessors who were
blinded to the woman’s allocated treatment group. Furthermore, both the content and intensity of the
intervention reflect one that could be realistically achieved within current public antenatal care services.
Participants in our trial were predominantly white Caucasian, with less than half of women from
areas of high social disadvantage. Furthermore, 75% of eligible women declined participation due
to time constraints, lack of interest or lack of perceived need. These factors may limit our external
validity and generalisability of our findings to other patient populations.
Our systematic review evaluating dietary and lifestyle interventions in pregnant women with
healthy BMI, providing a combined intervention was associated with a modest 1.25 kg difference in
weight gain (5 studies, 714 women) [34]. Overall, the methodological quality of the studies included
were of medium to high quality, and low to medium risk of bias [34]. The intensity and nature
of the intervention overall was poorly described, with nine interventions consisting of face-to-face
sessions with a trained professional [52–60]. The intensity ranged from three dietetic sessions over
pregnancy [58,59], up to one at each antenatal visit [61]. Three studies [52,54,58] provided an additional
session post-partum.
The findings of our current study are in contrast to this review [34], finding no clinically or
statistically significant difference in total gestational weight gain, or risk of weight gain below or above
the IOM recommendations. However, provision of dietary and lifestyle advice during pregnancy
was associated with improvements in maternal self-reported diet quality as measured by the HEI.
These findings are consistent with those we have reported previously from both the LIMIT [37,38] and
GROW [61] randomised trials, highlighting the reproducibility of the intervention among pregnant
women across the BMI spectrum in effecting dietary change.
Overall, however, our findings are consistent with the broader literature describing antenatal
dietary and lifestyle interventions in pregnant women across all BMI categories [62]. In a comprehensive
individual participant data meta-analysis utilising data from 36 randomised trials, and more than
12,500 pregnant women, a modest effect on GWG was identified following dietary and physical activity
advice (mean difference −0.7 kg), although there was very little effect on clinical pregnancy and
neonatal outcomes [62]. When considered in their totality, the available literature challenges the current
underlying rationale of providing an antenatal dietary and lifestyle intervention with the intention
of limiting weight gain as a means to improving pregnancy outcomes. GWG reflects a combination
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of maternal fat deposition, pregnancy related plasma volume expansion, breast and uterine tissue
hypertrophy, extracellular fluid, placental mass, foetal mass and amniotic fluid volume [63], and while
it has been considered a surrogate for adiposity gain in pregnancy, the evidence to date suggests that it
may not be readily modified simply through changes in maternal dietary intake and physical activity.
5. Conclusions
Our findings indicate that while providing lifestyle advice during pregnancy to women with BMI
within the normal range was associated with improvements in maternal diet quality, there were no
clinically or statistically significant differences in total gestational weight gain or in clinical outcomes
for either women or their infants. Providing such an intervention in pregnancy is not advocated.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/11/12/2911/s1,
Table S1: Maternal Quality of Life, Table S2: Infant anthropometry, and Table S3: Pre-specified analysis of effect
modification by maternal pre-pregnancy BMI.
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